Furthermore, the expression level of the anti-apoptotic protein Bcl-2, which is overexpressed in many tumors and drives tumorigenesis and chemoresistance, seems to be a determinant for the sensitivity of cancer cells to cisplatin (Fig. 3). This evidence concerns the gene BCL2 and cancer.